| Old Articles: <Older 3501-3510 Newer> |
|---|
 |
The Motley Fool
February 28, 2007
Brian Lawler |
Dynavax Down but Not Out Drug developer Dynavax gives guidance for 2007 after its lead drug candidate fails in clinical testing.   |
The Motley Fool
February 28, 2007
Brian Lawler |
No Dice for Novo Novo Nordisk reports a failed clinical trial for one of its top drugs. Shares were down more than 5% on the news. |
The Motley Fool
February 28, 2007
Brian Lawler |
Barr's Becoming Big Generic drug producer Barr Pharmaceuticals announces its first quarterly earnings numbers after acquiring Pliva. Investors, take note. |
The Motley Fool
February 28, 2007
Brian Lawler |
Merck's Mighty Future Merck ups its 2007 financial forecast, while positive developments occur for two of its most promising new therapies. |
The Motley Fool
February 27, 2007
Brian Lawler |
FDA Keeps Novartis Waiting The pharmaceutical experiences a regulatory setback in the U.S. for one of its top drug candidates. Investors, take note. |
InternetNews
February 26, 2007
Sean Michael Kerner |
Red Hat Gets a Healthy Option Linux vendor Red Hat has partnered with healthcare solutions provider McKesson to provide the Red Hat Enterprise Healthcare Platform. |
InternetNews
February 26, 2007
Michael Hickins |
Microsoft Plants Bigger Stakes in Health IT Medical search portal buy is one of several initiatives Microsoft is taking in the booming health care IT sector. |
The Motley Fool
February 26, 2007
Brian Lawler |
Waiting on AtheroGenics The results might be positive for this pharma, but don't bet on it. Investors, take note. |
The Motley Fool
February 26, 2007
Brian Lawler |
Shire's Busy Week Shire Pharmaceuticals announces year-end results, new regulatory approval, and another acquisition. |
The Motley Fool
February 22, 2007
Brian Lawler |
Too Much Aplomb From Elan Elan releases its 2006 financial results, and its future is not as rosy as seems. Investors, take note. |
| <Older 3501-3510 Newer> Return to current articles. |
